The HCPLive uveitis page is a comprehensive resource for clinical news and insights on chorioretinitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for eye inflammation, and more.
April 26th 2024
Both vaccine type and period mediated the risk of uveitis after COVID-19 vaccination in patients with a history of the ocular inflammatory event.
Acute Posterior Multifocal Placoid Pigment Epitheliopathy Developed in One Woman After Flu Vaccine
“To our knowledge, only one case of APMPPE following human influenza virus vaccine was reported, and this case reportedly demonstrated a benign clinical course.†The researchers encourage doctors to be aware, though this case was both benign and extremely rare.
Adalimumab: Efficacy and Adverse Effects for Patients with Active Noninfectious Uveitis
The authors say that for uveitis “there is a large unmet medical need" for identifying other therapies. Adalimumab is associated with decreased visual impairment and decreased risk of uveitic flare, but more adverse events, according the results from a recent multinational phase 3 trial.
Cases May Connect Bilateral Acute Simultaneous Onset Anterior Uveitis to Erlotinib
“These cases highlight a potential association between erlotinib therapy and bilateral, acute, simultaneous-onset anterior uveitis and suggest some patients may respond to topical corticosteroids, despite continued use of the drug.â€
Flying Eye Hospital Brings Invaluable Resources to Patients Worldwide
The treatment of various eye conditions can vary widely depending on where a patient lives. While some countries may have the best technology readily available others are lacking in not only equipment but training.
Golimumab Effective Against Uveitis Associated with Ankylosing Spondylitis
Retrospective study results indicate that golimumab may be a new and effective choice for maintaining remission and preventing recurrence of severe, recurrent anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis.
Study Shows TNF Inhibitors Prevent Relapse of Uveitis in Most Patients with Ankylosing Spondylitis
Adalimumab, infliximab, and etanercept, reduced the number of uveitis relapses in a retrospective, long-term study of uveitis patients with HLA-B27-positive ankylosing spondylitis who had taken one of these biological agents for at least 1 year.
Investigational Implant Halts Recurrence of Uveitis Inflammation, Improves Visual Acuity
A long-acting fluocinolone acetonide implant improved visual acuity and controlled intraocular inflammation for 2 years in 11 eyes of 11 patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.
Howard Schatz: Moving from the Operating Room to the Dark Room
It was supposed to be just a one year sabbatical for Howard Schatz to take a break from his work as a retina specialist and enjoy what had become a growing hobby of photography. More than two decades later Schatz said he misses some parts of practice but is greatly enjoying what has become a second career.
In a post hoc statistical analysis of data from 61 consecutive patients diagnosed with intermediate uveitis, the central foveal thickness cut-off value for starting systemic corticosteroid treatment was determined to be 215.5 μm. This value was found to have a sensitivity of 62.5% and a specificity of 96.4%.
Smaller Inserter Performs Well for Injectable Uveitis Treatment
A newer, smaller inserter has been shown to be even more effective for the delivery of Medidur than a previous slightly larger-gauge inserter, and none of 11 eyes implanted in Phase 2 showed signs of uveitis recurrence two years after the injection.
Aleksandra Rachitskaya from Cole Eye Institute: ARGUS II Provides Hope of New Vision for Patients
For patients with retinitis pigmentosa the loss of vision can be a difficult consequence of the condition. An implanted device may not give them back the sight they once had but it can provide a chance to see the world around them in a new way.
Aleksandra Rachitskaya: New Technologies Provide Hope for Visually Impaired Patients
As technology improves across the medical spectrum new devices, including implants, are providing help for patients who just a few years ago may not have had any treatment options available.
Hypotony May Signal Severe Uveitis in Juvenile Idiopathic Arthritis Patients
In a 30-year retrospective study of a cohort of patients with uveitis associated with juvenile idiopathic arthritis (JIA), risk factors for the development of hypotony during follow-up were associated with more severe uveitis. Because JIA-associated uveitis is often asymptomatic, hypotony may be a key indicator of uveitis in JIA patients.
Tarek Hassan: New Journal to Expand Education Efforts of ASRS
As new treatments and procedures are developed in the field of retinal medicine the American Society of Retina Specialists is launching its own journal to help its members and others in the field advance patient care.
The rate of endophthalmitis after more than 90,000 intravitreal injections was found to be approximately 1 in 3000 in a retrospective study of a consecutive series of cases at a multicenter, retina-only practice. Prophylactic use of topical antibiotics was not found to decrease this rate.
Assessing Rates of Noninfectious Vitritis after Intravitreal Injection of Anti-VEGF Agents
Although intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become the therapeutic mainstay for diabetic macular edema and neovascular age-related macular degeneration, it poses a risk of noninfectious uveitis or infectious endopthalmitis.
Oral Bisphosphonate Use Poses Risk of Wet Age-Related Macular Degeneration
Regular users of oral bisphosphonates had a higher risk of developing wet age-related macular degeneration than non-users, according to results of a recent Canadian study, and the longer the use, the greater the increased risk.